How to Get Retatrutide in 2026: Trials, FDA Timeline & Options

Before Eli Lilly can ask for approval, it needs to finish its main trials. Drug trials happen in phases: Phase 1 tests safety in a small group, Phase 2 checks if it works, and Phase 3 tests it in thousands of people to confirm everything. Retatrutide is in Phase 3.

The two biggest ongoing trials are TRIUMPH-1 (2,300 people with obesity) and TRIUMPH-2 (1,000 people with type 2 diabetes and obesity). Both should finish around mid-2026.

There is also a trial specifically testing whether retatrutide prevents heart attacks and strokes (TRIUMPH-3, 1,800 people), and a head-to-head trial comparing retatrutide directly against tirzepatide (the active ingredient in Zepbound) under identical conditions (NCT06662383, 800 patients). That comparison should have results by December 2026.

After the trials finish, Eli Lilly puts together a massive application (called a New Drug Application, or NDA) that includes all the safety and effectiveness data. Think of it as the company's homework proving the drug works and is safe enough to sell. This takes several months to prepare. Analysts expect Lilly to file in late 2026, though the company has not confirmed an exact date.

Once the FDA receives the application, it takes 10 months for a standard review. There is a faster track called Priority Review (6 months) for drugs that represent a major improvement over what is already available. Given that retatrutide produced nearly 29% weight loss, more than any existing drug, the faster review is possible. Earliest approval decision: mid-2027.

After approval, Eli Lilly needs a few more months to manufacture enough supply and negotiate insurance coverage. Based on Zepbound's launch (Lilly's other weight loss drug), expect a price around $1,000 or more per month before insurance. Lilly usually offers savings cards that can drop the cost significantly. Industry analysts project retatrutide will hit pharmacy shelves in 2028.

Eli Lilly's Phase 3 program includes eight trials spanning multiple conditions. Several are still recruiting participants.

Two places to search:

ClinicalTrials.gov: Go to clinicaltrials.gov and search for "retatrutide" or "LY3437943" (the research designation). Filter by location and recruiting status.

Eli Lilly Trial Finder: Visit trials.lilly.com for a more patient-friendly interface. You can enter your zip code and medical conditions to see matching trials.

Look for trials with "Recruiting" or "Enrolling by invitation" status. "Active, not recruiting" means the trial has filled its enrollment.

Most TRIUMPH trials require:

You need a BMI of 30 or higher. BMI is a number calculated from your height and weight. A 5'9" person weighing 203 lbs has a BMI of 30. You can also qualify with a BMI of 27 or higher if you have a weight-related health problem like high blood pressure, high cholesterol, sleep apnea, or heart disease. You must be at least 18 years old, and you must have tried to lose weight through diet or exercise before without lasting success.

You will likely be turned away if you have a history of pancreatitis (pancreas inflammation), a thyroid cancer called medullary thyroid carcinoma in your family, if you are pregnant, if your weight has changed by more than 11 lbs in the past 3 months, or if you are already taking a weight loss drug.

Contact the study coordinator listed on the trial page. They will walk you through a screening process: your medical history, blood tests, a physical exam, and a consent form.

One important thing to understand: you might not get the actual drug. In these trials, some participants receive a placebo (a fake injection with no active ingredient). This is how researchers prove the drug actually works, by comparing it against nothing. The trial is "double-blind," which means neither you nor your doctor knows whether you got the real drug or the placebo until the trial is over.

The upside: Free access to pharmaceutical-grade retatrutide (if you get the real drug and not the placebo), regular checkups, blood work, and health monitoring at no cost. You also help advance research for future patients.

The downside: You might get the placebo. Side effects are common: about 43% of people felt nauseous, 33% had diarrhea, and about 1 in 5 experienced tingling or burning skin sensations (called dysesthesia) at the highest dose. You will need to show up for clinic visits regularly, sometimes for over a year. You cannot pick your dose, and you need to live close enough to a trial site to attend in person.

For a full breakdown of what side effects to expect, see our retatrutide side effects guide.

Research peptide companies sell synthetic peptides as raw chemicals for laboratory use. The products typically arrive as a freeze-dried (lyophilized) powder in small vials, usually 5 mg or 10 mg. You would need to add sterile water to dissolve the powder before it could be used. Prices range from about $150 to $500 per month depending on the vendor and dose.

These companies source their peptides from chemical manufacturers, often based in China. The vials are labeled "for research purposes only, not for human consumption." This labeling is what allows them to sell the product without FDA approval, since technically they are selling a lab chemical, not a medicine.

In practice, many buyers purchase these peptides with the intention of self-administering them. This is an open secret in the peptide community. However, the "research use only" label means the product is not manufactured, tested, or regulated to pharmaceutical standards.

The core problem is quality control. Pharmaceutical-grade retatrutide (the version used in Eli Lilly's clinical trials) is made under strict manufacturing standards with rigorous purity testing. Research peptides are not held to those standards.

Purity is not guaranteed. The FDA has found heavy metals, bacterial toxins (endotoxins), wrong peptide sequences, and contamination in seized samples of GLP-1 peptides sold online. Some vials contained something completely different from what the label said (FDA, 2025).

There is no medical supervision. Even the real, pharmaceutical-grade retatrutide causes significant side effects: nausea in 43% of people, diarrhea in 33%, and unusual skin sensations (tingling, burning) in about 1 in 5 people at the highest dose. These numbers come from trials where patients were monitored by doctors. Self-administering an unverified version without medical oversight adds a layer of risk.

Dosing is guesswork. Without knowing the actual purity of what is in the vial, you cannot accurately dose. Underdosing means it will not work. Overdosing increases side effect risk.

Some research peptide vendors provide third-party certificates of analysis (COA) showing purity testing. These can be helpful, but they vary in reliability: some come from reputable independent labs, others are easy to fabricate.

Buying research peptides for personal research is a legal gray area. Selling them labeled "for research use only" is currently permitted. What is clearly illegal: marketing them for human use, making medical claims, or selling them as medicine.

The FDA is tightening enforcement. In September 2025, the agency issued over 50 warning letters to companies selling GLP-1 products (including retatrutide) with marketing that implied human use. In December 2025, Pinnacle Peptides received a warning letter for selling unapproved products (FDA Warning Letter). GenLabMeds got a similar letter in September 2025.

Congress is pushing to close loopholes. The SAFE Drugs Act, introduced in December 2025, would expand the FDA's power over compounded and unregulated GLP-1 products and the telehealth companies that prescribe them (Dykema analysis). US Customs can also seize peptide shipments at the border under Import Alert 66-80.

The Alliance for Pharmacy Compounding (the compounding industry's own trade group) has told its members twice: do not compound retatrutide.

US law only allows pharmacies to compound a drug if it meets certain conditions. Retatrutide fails all of them:

The FDA has said this directly: retatrutide "cannot be used in compounding under federal law." Any pharmacy making it is breaking federal law, no matter what their state laws say (Ohio Board of Pharmacy / FDA Letter).

Those drugs followed a different path. Semaglutide (Ozempic/Wegovy) got FDA approval, then demand outstripped supply, so it went on the "drug shortage list." That shortage list temporarily opened a legal door for compounding pharmacies to make their own versions. Tirzepatide (Mounjaro/Zepbound) followed the same path.

As of early 2026, the FDA has shut down tirzepatide compounding because the shortage is over. Semaglutide compounding is in a gray area.

Retatrutide has never been through any of these steps. It has never been approved, so it cannot be in "shortage," so there is no legal basis for compounding. Period.

Only if retatrutide gets FDA approval and then ends up on the drug shortage list, like semaglutide and tirzepatide did. But Eli Lilly has already shown it will fight compounders in court (the company has active lawsuits against pharmacies that compounded its other drugs). Congress is also moving to tighten the rules with the SAFE Drugs Act, which would cap compounding of copycat drugs at 20 units per month.

Tirzepatide is the closest available drug to retatrutide. It shares two of the three receptors (GLP-1 and GIP) and is made by the same company, Eli Lilly. FDA-approved for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023).

Weight loss: approximately 22.5% at 72 weeks in the SURMOUNT-1 trial. Cost: $299 to $1,086 per month depending on format. Eli Lilly's savings card can bring the price down to $25 per month for eligible patients. Plan your dosing with our tirzepatide dosage calculator. For a detailed comparison, see retatrutide vs tirzepatide.

Semaglutide is the original "new generation" weight loss drug. It activates one receptor (GLP-1) instead of two or three. Made by Novo Nordisk. You may know it as Ozempic (for diabetes) or Wegovy (for weight loss). It produces about 15 to 17% body weight loss over 16 months.

Semaglutide is the most widely prescribed option and has the longest safety track record. It also has a proven heart benefit: in a large trial, it reduced heart attacks and strokes by 20%. Use our semaglutide dosage calculator for dosing guidance.

Each generation of these drugs targets more receptors and produces more weight loss. The tradeoff is that more receptors also means more side effects, especially nausea and (for retatrutide) unusual skin sensations. For a broader view of peptide options, see our best peptides for weight loss guide.

Retatrutide is not the only next-generation weight loss drug in development. Several others are in late-stage testing:

Orforglipron (Eli Lilly): This one is a pill, not an injection. It works on the same GLP-1 receptor as Ozempic, but you swallow it daily instead of injecting weekly. Results are expected in 2026. If approved, this could be a game-changer for people who do not want to use needles.

Survodutide (Boehringer Ingelheim): Targets two receptors (GLP-1 and glucagon), like a simpler version of retatrutide. It showed about 15% weight loss in trials, with very promising results for reducing liver fat in people with fatty liver disease.

CagriSema (Novo Nordisk): A combination of two drugs (cagrilintide and semaglutide) that work through different pathways than retatrutide. Still in testing, results pending.

Tirzepatide and semaglutide are available today and produce meaningful weight loss (15 to 22.5%). If your insurance covers weight management medications, a prescription is a straightforward first step. If cost is a barrier, manufacturer savings cards can reduce Zepbound to $25 per month and Wegovy has similar programs.

Starting one of these medications now does not lock you in. Once retatrutide is approved, you could switch. Since both retatrutide and tirzepatide are made by Eli Lilly, the transition should be straightforward. You would start retatrutide at the lowest dose and gradually increase it (called titration), regardless of what dose of tirzepatide you were on. See our retatrutide dosage guide for how the dose increase works.

If you meet the eligibility criteria and live near a trial site, clinical trial enrollment gives you free access to pharmaceutical-grade retatrutide under close medical supervision. You may receive placebo, but even that comes with regular medical monitoring that many people do not otherwise get. See the step-by-step enrollment guide above.

If you have life-threatening obesity-related complications, are ineligible for clinical trials, and have exhausted all approved treatments, ask your physician to contact Eli Lilly at 1-800-545-5979 about expanded access. This is a narrow pathway, but it exists for the most severe cases.

Weight loss drugs work better when combined with healthier eating and more movement. Building that foundation now will amplify whatever medication you eventually take. Clinical trials also require that you have already tried to lose weight through diet and exercise, so documenting those efforts now helps if you apply later.

Start tracking a few basic numbers: your weight, waist measurement, and blood pressure. If you can, get bloodwork done (blood sugar and cholesterol levels). This gives you a starting point so you can actually measure how much a future treatment helps.

Key dates to watch in 2026: TRIUMPH-1 and TRIUMPH-2 results (mid-2026), head-to-head retatrutide vs tirzepatide results (December 2026), and any NDA filing announcements from Eli Lilly.

Set up free email alerts on ClinicalTrials.gov for "retatrutide" to be notified of new trial openings. Follow Eli Lilly's investor relations page for press releases. We will update this article as new data emerges. For dosing reference across all peptides, see the peptide dosage chart. For injection fundamentals, see the peptide injections complete guide.